Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complementation analysis of testis tumor cells

X Wang1, M Hafezparast, J R Masters

  • 1University College London, Institute of Urology and Nephrology, U.K.

Cancer Genetics and Cytogenetics
|October 6, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A mathematical understanding of how cytoplasmic dynein walks on microtubules.

Royal Society open science·2018
Same author

Plexin-B1 signalling promotes androgen receptor translocation to the nucleus.

Oncogene·2015
Same author

Prostate cancer stem cell therapy: hype or hope?

Prostate cancer and prostatic diseases·2008
Same author

Dynein-dynactin complex subunits are differentially localized in brain and spinal cord, with selective involvement in pathological features of neurodegenerative disease.

Neuropathology and applied neurobiology·2007
Same author

Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer.

Oncogene·2007
Same author

Genome-wide screening for genetic changes in a matched pair of benign and prostate cancer cell lines using array CGH.

Prostate cancer and prostatic diseases·2005

Testis tumor cells show sensitivity to cisplatin chemotherapy. This study found a single common mechanism controls cisplatin sensitivity in these cells, suggesting a unified therapeutic target.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Testis tumors are highly responsive to cisplatin-based chemotherapy, with over 80% of patients achieving cure.
  • Testis tumor cells maintain sensitivity to cisplatin in vitro, indicating intrinsic cellular mechanisms of drug response.
  • Understanding the genetic basis of cisplatin sensitivity is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To determine the number of genes controlling cisplatin sensitivity in testis tumor cells using complementation analysis.
  • To identify potential genetic targets for enhancing cisplatin efficacy in testicular cancer treatment.
  • To elucidate the molecular mechanisms underlying cisplatin resistance or sensitivity in germ cell tumors.

Main Methods:

  • Transfection of four testis tumor cell lines with resistance plasmids (pSV2NEO, pBABE).

Related Experiment Videos

  • Generation of self-crosses to control for gene dosage and confirmation of hybrid parentage via PCR.
  • Karyotyping to ensure chromosomal stability in hybrid cell lines (retaining at least 88% of parental chromosomes).
  • Measurement of cisplatin sensitivity using clonogenic assays.

    • Main Results:

    • Complementation analysis did not reveal genetic interactions controlling cisplatin sensitivity.
    • No evidence of multiple genes conferring cisplatin sensitivity was observed.
    • The study suggests a conserved genetic pathway influencing drug response in testis tumor cells.

    Conclusions:

    • A single, common mechanism likely governs cisplatin sensitivity in testis tumor cells.
    • This finding supports a unified approach to understanding and targeting cisplatin response in testicular cancers.
    • Further research can focus on identifying this singular genetic determinant for therapeutic development.